SOTAC

Sotac Pharmaceuticals Ltd Share Price

 

Stock Hit Upper Circuit

 

Start SIP in SOTAC

Start SIP

Performance

  • Low
  • ₹105
  • High
  • ₹105
  • 52 Week Low
  • ₹88
  • 52 Week High
  • ₹152
  • Open Price₹105
  • Previous Close₹100
  • Volume1,200
  • 50 DMA₹122.35
  • 100 DMA₹123.37
  • 200 DMA₹124.50

Investment Returns

  • Over 1 Month -14.91%
  • Over 3 Month -16%
  • Over 6 Month -15.32%
  • Over 1 Year -3.89%

Smart Investing Starts Here Start SIP with Sotac Pharmaceuticals Ltd for Steady Growth!

Invest Now

Sotac Pharmaceuticals Ltd Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.5
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 116
  • P/B Ratio
  • 2.5
  • Average True Range
  • 5.67
  • EPS
  • 6.95
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -2.34
  • RSI
  • 36.27
  • MFI
  • 52.65

Sotac Pharmaceuticals Ltd Financials

Sotac Pharmaceuticals Ltd Technicals

EMA & SMA

Current Price
₹105.00
+ 5 (5%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹118.40
  • 50 Day
  • ₹122.35
  • 100 Day
  • ₹123.37
  • 200 Day
  • ₹124.50

Resistance and Support

105 Pivot Speed
  • R3 105.00
  • R2 105.00
  • R1 105.00
  • S1 105.00
  • S2 105.00
  • S3 105.00

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sotac Pharmaceuticals Ltd has an operating revenue of Rs. 121.79 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of 11% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 106 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sotac Pharmaceuticals Ltd Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2025-05-28 Audited Results, Dividend & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2024-10-29 Quarterly Results
2024-08-13 Quarterly Results
2024-05-17 Audited Results & Others To consider other business matters Final Dividend of Rs. 0.1 per equity share.
Date Purpose Remarks
2025-09-19 FINAL Rs.0.00 Final Dividend of Rs. 0.1 per equity share.
View Sotac Pharmaceuticals Ltd Dividend History Arrow

Sotac Pharmaceuticals Ltd F&O

Sotac Pharmaceuticals Ltd Shareholding Pattern

72.85%
16.14%
5.12%
5.89%

About Sotac Pharmaceuticals Ltd

  • NSE Symbol
  • SOTAC
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Sharadkumar Dashrathbhai Patel
  • ISIN
  • INE0O2D01012

Similar Stocks to Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Ltd FAQs

Sotac Pharmaceuticals Ltd share price is ₹105 As on 24 January, 2026 | 03:28

The Market Cap of Sotac Pharmaceuticals Ltd is ₹116 Cr As on 24 January, 2026 | 03:28

The P/E ratio of Sotac Pharmaceuticals Ltd is 14.5 As on 24 January, 2026 | 03:28

The PB ratio of Sotac Pharmaceuticals Ltd is 2.5 As on 24 January, 2026 | 03:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23